Trial Profile
An Open-label Multiple Dose Study To Evaluate The Pharmacokinetics, Safety And Tolerability Of CP-690,550 In Pediatric Patients From 2 To Less Than 18 Years Of Age With Juvenile Idiopathic Arthritis (JIA)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 24 Dec 2021
Price :
$35
*
At a glance
- Drugs Tofacitinib (Primary)
- Indications Juvenile rheumatoid arthritis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Pfizer
- 06 Jun 2020 Results describing tofacitinib pharmacokinetics (PK) in patients with JIA, identifying potential covariates accounting for variability in exposure, assessing the formulation effect of oral solution vs tablet and propose a simplified dosing regimen presented at the 21st Annual Congress of the European League Against Rheumatism
- 05 Jan 2016 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 02 Nov 2015 Planned primary completion date changed from 1 Sep 2015 to 1 Dec 2015, according to ClinicalTrials.gov record.